Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revascor in LVAD Bridge to Transplant
NCT00927784Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2009
- Primary completion
- May 2010
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rexlemestrocel-l in heart failure (HF) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Incidence of Infectious Myocarditis at 90 days, Incidence of Myocardial Rupture at 90 days and 3 more. Started Aug 2009; status: terminated.
02
Drugs
rexlemestrocel-l
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00927784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927784.